

KIT FOR PREDICTING THE RESPONSE TO TREATMENT IN PATIENTS WITH RECTAL CANCER

Summary of the offer

A research group of the Andalusian Public Health System has developed a test kit to predict the response to neoadjuvant therapy in patients with rectal cancer.

Description of the offer

Current treatment strategies combine surgery with neoadjuvant radiotherapy and chemotherapy. Conventional techniques have not succeeded in predicting the clinical response to these treatments.

The research group has developed a kit that analyses the expression of a number of selected genes from peripheral blood samples. These expression levels enable the identification of those patients who will respond positively to treatment.

Advantages of the offer

1. Prediction of therapy response, enabling the identification of candidates for neoadjuvant therapy.
2. A systematic and standardised estimation of the response.

3. Relies on a non-invasive method, since the samples are taken from peripheral blood.
4. Enables the selection of patient groups.
5. Increased cost-effectiveness.

Intellectual Property

This technology is protected by patent.

What we are looking for?

We are looking for a partner interested in a license and/or a collaboration agreement to further develop and exploit this innovative technology.

Classification

Category: Diagnostic

Subcategory: Cancer or oncology



FUNDACIÓN PÚBLICA ANDALUZA PARA LA INVESTIGACIÓN BIOSANITARIA DE ANDALUCÍA ORIENTAL ALEJANDRO OTERO

C/ Dr. Azpitarte, 4, 4ª planta. Edificio Licinio de la frente 18012 .Granada

+34 958 020 245 MÓVIL +34 608 376 697 pablo.alvarez.exts@juntadeandalucia.es

